{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T17:39:24Z","timestamp":1791394764005,"version":"4.3.3"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T00:00:00Z","timestamp":1681430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s10072-023-06795-9","type":"journal-article","created":{"date-parts":[[2023,4,14]],"date-time":"2023-04-14T03:40:58Z","timestamp":1681443658000},"page":"3059-3069","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis"],"prefix":"10.1007","volume":"44","author":[{"given":"Sahar","family":"Ghorbanpour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarvenaz","family":"Rahimibarghani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Rohani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Rastkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-8852","authenticated-orcid":false,"given":"Mahsa","family":"Ghajarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,14]]},"reference":[{"issue":"12","key":"6795_CR1","first-page":"1582","volume":"5","author":"P Sarraf","year":"2014","unstructured":"Sarraf P, Azizi S, Moghaddasi AN, Sahraian MA, Tafakhori A, Ghajarzadeh M (2014) Relationship between sleep quality and quality of life in patients with multiple sclerosis. Int J Prev Med 5(12):1582","journal-title":"Int J Prev Med"},{"issue":"5","key":"6795_CR2","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11910-011-0214-y","volume":"11","author":"MH Cameron","year":"2011","unstructured":"Cameron MH, Wagner JM (2011) Gait abnormalities in multiple sclerosis: pathogenesis, evaluation, and advances in treatment. Curr Neurol Neurosci Rep 11(5):507\u2013515","journal-title":"Curr Neurol Neurosci Rep"},{"key":"6795_CR3","first-page":"22","volume":"3","author":"JA Cohen","year":"2007","unstructured":"Cohen JA, Rudick RA (2007) Aspects of multiple sclerosis that relate to trial design and clinical management. Multiple Sclerosis Therapeutics 3:22","journal-title":"Multiple Sclerosis Therapeutics"},{"issue":"3","key":"6795_CR4","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/brain\/awl007","volume":"129","author":"C Confavreux","year":"2006","unstructured":"Confavreux C, Vukusic S (2006) Natural history of multiple sclerosis: a unifying concept. Brain 129(3):606\u2013616","journal-title":"Brain"},{"issue":"9665","key":"6795_CR5","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. The Lancet 373(9665):732\u2013738","journal-title":"The Lancet"},{"issue":"7","key":"6795_CR6","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1185\/03007995.2011.583229","volume":"27","author":"J Dunn","year":"2011","unstructured":"Dunn J, Blight A (2011) Dalfampridine: a brief review of its mechanism of action and efficacy as a treatment to improve walking in patients with multiple sclerosis. Curr Med Res Opin 27(7):1415\u20131423","journal-title":"Curr Med Res Opin"},{"key":"6795_CR7","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jns.2015.11.035","volume":"360","author":"Z Savin","year":"2016","unstructured":"Savin Z, Lejbkowicz I, Glass-Marmor L, Lavi I, Rosenblum S, Miller A (2016) Effect of fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with multiple sclerosis. J Neurol Sci 360:102\u2013109","journal-title":"J Neurol Sci"},{"issue":"5","key":"6795_CR8","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00415-018-8796-9","volume":"265","author":"SD Broicher","year":"2018","unstructured":"Broicher SD, Filli L, Geisseler O, Germann N, Z\u00f6rner B, Brugger P et al (2018) Positive effects of fampridine on cognition, fatigue and depression in patients with multiple sclerosis over 2 years. J Neurol 265(5):1016\u20131025","journal-title":"J Neurol"},{"issue":"9","key":"6795_CR9","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.1944","volume":"22","author":"MT Henkens","year":"2020","unstructured":"Henkens MT, Remmelzwaal S, Robinson EL, van Ballegooijen AJ, Barandiar\u00e1nAizpurua A, Verdonschot JA et al (2020) Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction A systematic review. Eur J Heart Failure 22(9):1586\u20131597","journal-title":"Eur J Heart Failure"},{"issue":"1","key":"6795_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2288-8-22","volume":"8","author":"A Lundh","year":"2008","unstructured":"Lundh A, G\u00f8tzsche PC (2008) Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 8(1):1\u20139","journal-title":"BMC Med Res Methodol"},{"issue":"2","key":"6795_CR11","first-page":"283","volume":"41","author":"B Mejuto","year":"2017","unstructured":"Mejuto B, Castellano P, Castro C, L\u00f3pez LM (2017) Assessment of the efficacy and safety of fampridine. Farm Hosp 41(2):283\u2013291","journal-title":"Farm Hosp"},{"issue":"14","key":"6795_CR12","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1177\/1352458514533844","volume":"20","author":"HB Jensen","year":"2014","unstructured":"Jensen HB, Ravnborg M, Mamoei S, Dalgas U, Stenager E (2014) Changes in cognition, arm function and lower body function after slow-release Fampridine treatment. Mult Scler J 20(14):1872\u20131880","journal-title":"Mult Scler J"},{"issue":"2","key":"6795_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2217\/nmt-2015-0004","volume":"6","author":"E Costa-Arp\u00edn","year":"2016","unstructured":"Costa-Arp\u00edn E, Pato A, Rodr\u00edguez-Regal A, Midaglia L, Y\u00e1\u00f1ez R, Mu\u00f1oz D et al (2016) Clinical response and tolerability of fampridine in clinical practice. Neurodegenerative Dis Manag 6(2):99\u2013105","journal-title":"Neurodegenerative Dis Manag"},{"issue":"12","key":"6795_CR14","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3390\/brainsci9120357","volume":"9","author":"R Ahdab","year":"2019","unstructured":"Ahdab R, Shatila MM, Shatila AR, Khazen G, Freiha J, Salem M et al (2019) Cortical excitability measures may predict clinical response to fampridine in patients with multiple sclerosis and gait impairment. Brain Sci 9(12):357","journal-title":"Brain Sci"},{"issue":"1","key":"6795_CR15","doi-asserted-by":"publisher","first-page":"e00559","DOI":"10.1002\/brb3.559","volume":"7","author":"M Korsen","year":"2017","unstructured":"Korsen M, Kunz R, Schminke U, Runge U, Kohlmann T, Dressel A (2017) Dalfampridine effects on cognition, fatigue, and dexterity. Brain and behavior 7(1):e00559","journal-title":"Brain and behavior"},{"issue":"6","key":"6795_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1177\/1352458513507356","volume":"20","author":"MH Cameron","year":"2014","unstructured":"Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R (2014) Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study. Mult Scler J 20(6):733\u2013738","journal-title":"Mult Scler J"},{"issue":"1","key":"6795_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-015-0431-0","volume":"15","author":"PM Keune","year":"2015","unstructured":"Keune PM, Cocks AJ, Young WR, Burschka JM, Hansen S, Hofstadt-van Oy U et al (2015) Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurol 15(1):1\u20138","journal-title":"BMC Neurol"},{"key":"6795_CR18","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jns.2016.06.019","volume":"368","author":"L Brambilla","year":"2016","unstructured":"Brambilla L, Sebastiano DR, Aquino D, Clerici VT, Brenna G, Moscatelli M et al (2016) Early effect of dalfampridine in patients with MS: a multi-instrumental approach to better investigate responsiveness. J Neurol Sci 368:402\u2013407","journal-title":"J Neurol Sci"},{"key":"6795_CR19","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.msard.2016.07.019","volume":"10","author":"H Jensen","year":"2016","unstructured":"Jensen H, Nielsen J, Ravnborg M, Dalgas U, Aagaard P, Stenager E (2016) Effect of slow release-Fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients A randomized, double blind, placebo controlled study. Multiple Sclerosis and Related Disorders 10:137\u2013144","journal-title":"Multiple Sclerosis and Related Disorders"},{"key":"6795_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.jns.2016.07.051","volume":"368","author":"J-P Stellmann","year":"2016","unstructured":"Stellmann J-P, Jlussi M, Neuhaus A, Lederer C, Daumer M, Heesen C (2016) Fampridine and real-life walking in multiple sclerosis: low predictive value of clinical test for habitual short-term changes. J Neurol Sci 368:318\u2013325","journal-title":"J Neurol Sci"},{"issue":"1","key":"6795_CR21","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.clinph.2016.10.088","volume":"128","author":"H Pickering","year":"2017","unstructured":"Pickering H, Murray J, Lin CS-Y, Cormack C, Martin A, Kiernan MC et al (2017) Fampridine treatment and walking distance in multiple sclerosis: a randomised controlled trial. Clin Neurophysiol 128(1):93\u201399","journal-title":"Clin Neurophysiol"},{"issue":"7","key":"6795_CR22","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1177\/1352458515606809","volume":"22","author":"R Macdonell","year":"2016","unstructured":"Macdonell R, Nagels G, Laplaud D-A, Pozzilli C, de Jong B, Martins da Silva A et al (2016) Improved patient-reported health impact of multiple sclerosis: the ENABLE study of PR-fampridine. Multiple Sclerosis J 22(7):944\u2013954","journal-title":"Multiple Sclerosis J"},{"issue":"1\u20132","key":"6795_CR23","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jns.2013.11.011","volume":"337","author":"T Ruck","year":"2014","unstructured":"Ruck T, Bittner S, Simon O, G\u00f6bel K, Wiendl H, Schilling M et al (2014) Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci 337(1\u20132):18\u201324","journal-title":"J Neurol Sci"},{"issue":"3","key":"6795_CR24","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40271-014-0102-z","volume":"8","author":"H Crayton","year":"2015","unstructured":"Crayton H, Sidovar M, Wulf S, Guo A (2015) Patient perspectives and experience with dalfampridine treatment in multiple sclerosis-related walking impairment: the step together program. The Patient-Patient-Centered Outcomes Res 8(3):283\u2013291","journal-title":"The Patient-Patient-Centered Outcomes Res"},{"key":"6795_CR25","doi-asserted-by":"publisher","first-page":"101489","DOI":"10.1016\/j.msard.2019.101489","volume":"38","author":"C van Munster","year":"2020","unstructured":"van Munster C, Kaya L, Lam K, Kalkers N, Killestein J, Uitdehaag B (2020) Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making. Multiple Sclerosis and Related Disorders 38:101489","journal-title":"Multiple Sclerosis and Related Disorders"},{"issue":"2","key":"6795_CR26","doi-asserted-by":"publisher","first-page":"301","DOI":"10.3233\/NRE-161361","volume":"39","author":"YD Fragoso","year":"2016","unstructured":"Fragoso YD, Adoni T, Alves-Leon SV, Apostolos-Pereira SL, Barreira AA, Brooks JBB et al (2016) Real-life experience with fampridine (Fampyra\u00ae) for patients with multiple sclerosis and gait disorders. NeuroRehabilitation 39(2):301\u2013304","journal-title":"NeuroRehabilitation"},{"issue":"3","key":"6795_CR27","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40268-013-0020-x","volume":"13","author":"MH Rabadi","year":"2013","unstructured":"Rabadi MH, Kreymborg K, Vincent AS (2013) Sustained-release fampridine (4-aminopyridine) in multiple sclerosis: efficacy and impact on motor function. Drugs R&D 13(3):175\u2013181","journal-title":"Drugs R&D"},{"issue":"15","key":"6795_CR28","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1080\/09638288.2017.1309581","volume":"40","author":"K Behm","year":"2018","unstructured":"Behm K, Morgan P (2018) The effect of symptom-controlling medication on gait outcomes in people with multiple sclerosis: a systematic review. Disabil Rehabil 40(15):1733\u20131744","journal-title":"Disabil Rehabil"},{"issue":"11","key":"6795_CR29","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s40263-019-00671-x","volume":"33","author":"M Valet","year":"2019","unstructured":"Valet M, Quoilin M, Lejeune T, Stoquart G, Van Pesch V, El Sankari S et al (2019) Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 33(11):1087\u20131099","journal-title":"CNS Drugs"},{"issue":"4","key":"6795_CR30","doi-asserted-by":"publisher","first-page":"170","DOI":"10.7224\/1537-2073.2015-035","volume":"18","author":"TR Brown","year":"2016","unstructured":"Brown TR, Simnad VI (2016) A randomized crossover trial of dalfampridine extended release for effect on ambulatory activity in people with multiple sclerosis. Int J MS care 18(4):170\u2013176","journal-title":"Int J MS care"},{"issue":"4","key":"6795_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","volume":"68","author":"AD Goodman","year":"2010","unstructured":"Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68(4):494\u2013502","journal-title":"Ann Neurol"},{"issue":"1","key":"6795_CR32","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/1352458518815795","volume":"26","author":"N Satchidanand","year":"2020","unstructured":"Satchidanand N, Drake A, Smerbeck A, Hojnacki D, Kolb C, Patrick K et al (2020) Dalfampridine benefits ambulation but not cognition in multiple sclerosis. Mult Scler J 26(1):91\u201398","journal-title":"Mult Scler J"},{"issue":"1","key":"6795_CR33","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/j.pharmthera.2005.10.006","volume":"111","author":"SI Judge","year":"2006","unstructured":"Judge SI, Bever CT Jr (2006) Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment. Pharmacol Ther 111(1):224\u2013259","journal-title":"Pharmacol Ther"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-023-06795-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-023-06795-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T06:44:41Z","timestamp":1691649881000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-023-06795-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,14]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["6795"],"URL":"https:\/\/doi.org\/10.1007\/s10072-023-06795-9","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,14]]},"assertion":[{"value":"1 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}